You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,086,011


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,086,011
Title:Combination formulation of two antiviral compounds
Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: ##STR00001## and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
Inventor(s): Gorman; Eric (San Francisco, CA), Mogalian; Erik (San Francisco, CA), Oliyai; Reza (Burlingame, CA), Stefanidis; Dimitrios (Saratoga, CA), Wiser; Lauren (San Francisco, CA), Zia; Vahid (Palo Alto, CA)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:15/670,283
Patent Claims: 1. A method of treating hepatitis C in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises: a) from about 1% to about 25% w/w of a solid dispersion comprising Compound I dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of Compound I to copovidone in the solid dispersion is about 1:1 and wherein Compound I is substantially amorphous having the formula: ##STR00018## b) from about 35% to about 45% w/w of substantially crystalline sofosbuvir having the formula: ##STR00019## c) from about 30% to about 40% w/w of microcrystalline cellulose; d) from about 1% to about 5% w/w of croscarmellose sodium; and e) from about 0.5% to about 2.5% w/w of magnesium stearate.

2. The method of claim 1, wherein the crystalline sofosbuvir has XRPD 2.theta.-reflections at about: 6.1 and 12.7.degree. 2.theta..+-.0.2.

3. The method of claim 1, wherein the crystalline sofosbuvir has XRPD 2.theta.-reflections at about: 6.1, 20.1, and 20.8.degree. 2.theta..+-.0.2.

4. The method of claim 1, wherein the pharmaceutical composition comprises about 40% w/w of sofosbuvir.

5. The method of claim 1, wherein the pharmaceutical composition comprises about 20% w/w of the solid dispersion.

6. The method of claim 1, wherein the pharmaceutical composition comprises about 35.5% w/w of microcrystalline cellulose.

7. The method of claim 1, wherein the pharmaceutical composition comprises about 3% w/w of croscarmellose sodium.

8. The method of claim 1, wherein the pharmaceutical composition comprises about 1.5% w/w of magnesium stearate.

9. The method of claim 1, wherein the pharmaceutical composition is administered for about 12 weeks.

10. A method of treating hepatitis C in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises: a) about 20% w/w of a solid dispersion comprising Compound I dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of Compound I to copovidone in the solid dispersion is about 1:1 and wherein Compound I is substantially amorphous having the formula: ##STR00020## b) about 40% w/w of substantially crystalline sofosbuvir having the formula: ##STR00021## c) about 35.5% w/w of microcrystalline cellulose; d) about 3% w/w of croscarmellose sodium; and e) about 1.5% w/w of magnesium stearate.

11. The method of claim 10, wherein the crystalline sofosbuvir has XRPD 2.theta.-reflections at about: 6.1 and 12.7.degree. 2.theta..+-.0.2.

12. The method of claim 10, wherein the crystalline sofosbuvir has XRPD 2.theta.-reflections at about: 6.1, 20.1, and 20.8.degree. 2.theta..+-.0.2.

13. The method of claim 10, wherein the pharmaceutical composition is administered for about 12 weeks.

14. A method of treating hepatitis C in a human patient in need thereof comprising administering to the patient a pharmaceutical composition, wherein the pharmaceutical composition comprises: a) about 200 mg of a solid dispersion comprising Compound I dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of Compound I to copovidone in the solid dispersion is about 1:1 and wherein Compound I is substantially amorphous having the formula: ##STR00022## b) about 400 mg of substantially crystalline sofosbuvir having the formula: ##STR00023## c) about 355 mg of microcrystalline cellulose; d) about 30 mg of croscarmellose sodium; and e) about 15 mg of magnesium stearate.

15. The method of claim 14 wherein the pharmaceutical composition is in the form of a tablet comprising a film coating.

16. The method of claim 15, wherein the film coating is a polyvinylalcohol-based coating.

17. The method of claim 14, wherein the crystalline sofosbuvir has XRPD 2.theta.-reflections at about: 6.1 and 12.7.degree. 2.theta..+-.0.2.

18. The method of claim 14, wherein the crystalline sofosbuvir has XRPD 2.theta.-reflections at about: 6.1, 20.1, and 20.8.degree. 2.theta..+-.0.2.

19. The method of claim 14, wherein the pharmaceutical composition is administered for about 12 weeks.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.